Short Interest in Affimed (NASDAQ:AFMD) Declines By 12.3%

Affimed (NASDAQ:AFMD) was the recipient of a significant drop in short interest during the month of January. As of January 15th, there was short interest totalling 742,900 shares, a drop of 12.3% from the December 31st total of 846,900 shares. Based on an average daily volume of 291,200 shares, the short-interest ratio is presently 2.6 days. Currently, 5.7% of the company’s shares are short sold.

Hedge Funds Weigh In On Affimed

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Jane Street Group LLC acquired a new stake in shares of Affimed during the third quarter worth about $44,000. FMR LLC increased its stake in Affimed by 30.0% during the 3rd quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock worth $59,000 after buying an additional 4,086 shares during the period. Intellectus Partners LLC lifted its holdings in Affimed by 12.2% during the 3rd quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock worth $317,000 after buying an additional 10,250 shares in the last quarter. Finally, Point72 Asset Management L.P. boosted its position in Affimed by 4.6% in the 3rd quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock valued at $1,152,000 after buying an additional 15,108 shares during the period. 30.82% of the stock is currently owned by hedge funds and other institutional investors.

Affimed Trading Down 2.1 %

NASDAQ:AFMD opened at $0.98 on Friday. Affimed has a fifty-two week low of $0.92 and a fifty-two week high of $8.95. The company has a quick ratio of 1.93, a current ratio of 1.93 and a debt-to-equity ratio of 0.13. The company has a 50 day moving average price of $1.64 and a 200 day moving average price of $3.12.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on AFMD shares. Stifel Nicolaus decreased their target price on shares of Affimed from $5.00 to $4.00 and set a “hold” rating on the stock in a report on Friday, November 15th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Affimed in a report on Tuesday, November 19th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Affimed in a research report on Tuesday, December 10th. Finally, Wells Fargo & Company reduced their target price on Affimed from $20.00 to $15.00 and set an “overweight” rating on the stock in a research report on Thursday, December 12th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $13.50.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.